Lunsekimig
- Generic Name
- Lunsekimig
Sanofi Advances Respiratory Pipeline with Promising Amlitelimab Data in Heterogeneous Inflammatory Asthma
• Sanofi's amlitelimab demonstrated clinically meaningful efficacy in heterogeneous inflammatory asthma, showing over 70% reduction in exacerbations in patients with specific biomarkers at week 60 of the TIDE-Asthma phase 2 study.
• The company is expanding its respiratory portfolio with lunsekimig now targeting chronic rhinosinusitis and COPD alongside asthma, with phase 2 readouts anticipated in 2026.
• Itepekimab, developed in partnership with Regeneron, is broadening its clinical program beyond COPD into chronic rhinosinusitis, with phase 3 readouts in COPD expected in H2 2025.
Sanofi's Lunsekimig (SAR443765) Receives CDSCO Panel Nod for Phase 2 Asthma Trial
• Sanofi Healthcare has received approval from the CDSCO panel in India to conduct a Phase 2 clinical trial for SAR443765 (lunsekimig) in asthma patients.
• The trial is an open-label extension study evaluating the long-term safety and efficacy of lunsekimig in adults with moderate-to-severe asthma.
• Lunsekimig is a novel anti-TSLP/anti-IL-13 nanobody molecule that has shown promise in reducing FeNO levels in asthma patients.
• The Phase 2 trial aims to further assess lunsekimig's potential to improve lung function, particularly in small airway dysfunction associated with type 2 inflammation.
Sanofi's Q3 Sales Surge 15.7% Driven by Vaccines and Dupixent; 2024 EPS Guidance Raised
• Sanofi reported a robust 15.7% sales growth in Q3, fueled by strong vaccine sales and the continued success of Dupixent, with sales up 23.8% to €3,476 million.
• Pharma launches, including ALTUVIIIO, Nexviazyme, and Rezurock, saw a significant 67.1% increase, contributing €727 million to the overall sales growth.
• The company's pipeline advanced with four regulatory approvals, including Dupixent for COPD in the US and China, and four positive Phase 3 data readouts, including tolebrutinib for nrSPMS.
• Based on strong Q3 business performance, Sanofi has raised its 2024 business EPS guidance to at least a low single-digit percentage growth at CER.
Johnson & Johnson to Acquire Yellow Jersey Therapeutics for $1.25 Billion, Bolstering Atopic Dermatitis Pipeline
• Johnson & Johnson will acquire Yellow Jersey Therapeutics for $1.25 billion, gaining rights to NM26, a Phase 2-ready bispecific antibody for atopic dermatitis.
• NM26 targets both IL-4Rα and IL-31, addressing inflammation and itch, potentially offering advantages over existing treatments like Dupixent.
• The acquisition aligns with J&J's strategy to expand its immunology portfolio with differentiated bispecifics, following recent deals in oncology and immunology.
• Numab Therapeutics' MATCH™ technology platform, used to develop NM26, is validated by this deal, highlighting its potential for creating novel multi-specific antibodies.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath